Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study
Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study
Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
60
Years old
Gender
All
Therapeutic area :
Cardiovascular
Disease :
QT prolongation
Study medication :
V0067
Phase :
Phase II
Start Date :
October 07, 2009
End date :
May 25, 2010
Study ID :
V00067 CA 201 1A
EudraCT/CTIS number :
2009-011819-20
Send by email